Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

7.900 +0.280 (+3.67%)
Delayed Quote Updated: 10:32 AM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
REGENXBIO Q3 Earnings Call Highlights ↗
REGENXBIO (NASDAQ:RGNX) is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the... 
Via MarketBeat
Topics Earnings
News headline image
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript ↗
Royalty declines and a litigation gain shaped the quarter's results. 
Via The Motley Fool
Topics Earnings Intellectual Property
REGENXBIO (NASDAQ:RGNX) Q3 2026: Narrower Loss Offsets Revenue Miss as Shares Rise Premarket ↗
Via Chartmill
News headline image
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy ↗
REGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or... 
Via MarketBeat
REGENXBIO (NASDAQ:RGNX) Beats Q2 EPS but Misses Revenue; Duchenne Gene Therapy Timeline Reaffirmed ↗
Via Chartmill
REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results ↗
Via Chartmill
News headline image
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
From Johnson Fistel, PLLP
Via Business Wire
Top movers in Monday's session ↗
Via Chartmill
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
REGENXBIO Q2 Earnings Call Highlights ↗
REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an... 
Via MarketBeat
Topics Earnings
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Regenxbio (RGNX) Q1 2026 Earnings Transcript ↗
Regenxbio (RGNX) Q1 2026 Earnings Transcript 
Via The Motley Fool
These stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which stocks are gapping on Thursday? ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.